




Product Use Management


MTN Annual Meeting
16 March 2010




VOICE Product Use Management: Grade 3 Adverse Events
ORAL and VAGINAL Study Product
Under Letter of Amendment #02




VOICE Product Use Management: Grade 4 Adverse Events
ORAL and VAGINAL Study Product
Under Letter of Amendment #02




VOICE Product Use Management: Nausea , Vomiting, and/or Diarrhea
VAGINAL Study Product
Under Letter of Amendment #02



VOICE Product Use Management: AST or ALT Elevation
VAGINAL Study Product
Under Letter of Amendment #02




VOICE Product Use Management: Grade 4 AST or ALT Elevation
ORAL Study Product
Under Letter of Amendment #02



VOICE Product Use Management: Grade 3 Hypophosphatemia

ORAL Study Product

Under Letter of Amendment #02




*Urine dipstick results of 1+ will be managed according to guidance in Sections 9.6 (for proteinuria) and 9.7 (for glycosuria). Findings of proteinuria and/or glycosuria of 2+ require consultation with the PSRT for the participant's further testing and management.

VOICE Product Use Management: Grade 4 Hypophosphatemia

ORAL Study Product

Under Letter of Amendment #02



got questions?